Endothelial Heme Dynamics Drive Cancer Cell Metabolism by Shaping the Tumor Microenvironment.
FLVCR1a
cancer cell metabolism
endothelial cell metabolism
heme metabolism
ketone bodies
tumor endothelial cells
tumor microenvironment
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
28 Oct 2021
28 Oct 2021
Historique:
received:
14
09
2021
revised:
24
10
2021
accepted:
25
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
The crosstalk among cancer cells (CCs) and stromal cells within the tumor microenvironment (TME) has a prominent role in cancer progression. The significance of endothelial cells (ECs) in this scenario relies on multiple vascular functions. By forming new blood vessels, ECs support tumor growth. In addition to their angiogenic properties, tumor-associated ECs (TECs) establish a unique vascular niche that actively modulates cancer development by shuttling a selected pattern of factors and metabolites to the CC. The profile of secreted metabolites is strictly dependent on the metabolic status of the cell, which is markedly perturbed in TECs. Recent evidence highlights the involvement of heme metabolism in the regulation of energy metabolism in TECs. The present study shows that interfering with endothelial heme metabolism by targeting the cell membrane heme exporter Feline Leukemia Virus subgroup C Receptor 1a (FLVCR1a) in TECs, resulted in enhanced fatty acid oxidation (FAO). Moreover, FAO-derived acetyl-CoA was partly consumed through ketogenesis, resulting in ketone bodies (KBs) accumulation in FLVCR1a-deficient TECs. Finally, the results from this study also demonstrate that TECs-derived KBs can be secreted in the extracellular environment, inducing a metabolic rewiring in the CC. Taken together, these data may contribute to finding new metabolic vulnerabilities for cancer therapy.
Identifiants
pubmed: 34829786
pii: biomedicines9111557
doi: 10.3390/biomedicines9111557
pmc: PMC8615489
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : IG18157
Organisme : Italian Association for Cancer Research
ID : IG24922
Organisme : Italian Association for Cancer Research
ID : IG21408
Références
Diabetes Res Clin Pract. 2014 Nov;106(2):173-81
pubmed: 25193333
Cell Cycle. 2010 Sep 1;9(17):3506-14
pubmed: 20818174
J Clin Invest. 2012 Dec;122(12):4569-79
pubmed: 23187127
Haematologica. 2015 Jun;100(6):720-9
pubmed: 25795718
J Pediatr Surg. 2009 Jan;44(1):212-6; discussion 216
pubmed: 19159745
Dev Cell. 2020 Jul 20;54(2):183-195
pubmed: 32640203
Oncogene. 2020 Apr;39(16):3292-3304
pubmed: 32071396
Cell Metab. 2017 Feb 7;25(2):262-284
pubmed: 28178565
Circ Res. 2015 Mar 27;116(7):1231-44
pubmed: 25814684
Cell Rep. 2016 Jun 21;15(12):2705-18
pubmed: 27292634
Cancer Cell. 2016 Dec 12;30(6):968-985
pubmed: 27866851
Nature. 2016 Jan 21;529(7586):316-25
pubmed: 26791722
Cancers (Basel). 2019 Jun 01;11(6):
pubmed: 31159426
Int J Mol Sci. 2018 Apr 24;19(5):
pubmed: 29695087
Int J Cancer. 2014 Oct 1;135(7):1711-20
pubmed: 24615175
Pharmacol Res. 2019 Dec;150:104500
pubmed: 31629092
Anal Biochem. 2002 Dec 15;311(2):139-51
pubmed: 12470673
Anal Biochem. 2009 Jan 1;384(1):145-50
pubmed: 18835235
Biochim Biophys Acta. 2004 Sep 6;1690(1):85-91
pubmed: 15337174
Cell Rep. 2021 Jun 15;35(11):109252
pubmed: 34133926
Cell Cycle. 2012 Nov 1;11(21):3964-71
pubmed: 23082722
Oncol Rep. 2006 Feb;15(2):381-6
pubmed: 16391858
Cancer Res. 2016 Sep 15;76(18):5201-8
pubmed: 27587539
Recent Pat Anticancer Drug Discov. 2018;13(4):422-427
pubmed: 29807523
Neurosci Biobehav Rev. 2021 May;124:124-136
pubmed: 33545213
J Lipid Res. 2018 Apr;59(4):625-634
pubmed: 29414764
FASEB J. 2003 Jun;17(9):1159-61
pubmed: 12709414
J Transl Med. 2020 Feb 3;18(1):52
pubmed: 32014047
Cell Metab. 2019 Sep 3;30(3):414-433
pubmed: 31484054
Cell Metab. 2018 Oct 2;28(4):573-587.e13
pubmed: 30017355
Trends Cell Biol. 2018 Mar;28(3):224-236
pubmed: 29153487
Front Neurosci. 2018 Oct 09;12:712
pubmed: 30356807
Cell Death Differ. 2018 Mar;25(3):573-588
pubmed: 29229999
Cancer Discov. 2012 Oct;2(10):881-98
pubmed: 23009760
JCI Insight. 2021 Oct 22;6(20):
pubmed: 34499623
Front Oncol. 2020 Jan 15;9:1540
pubmed: 32010627
Trends Endocrinol Metab. 2014 Jan;25(1):42-52
pubmed: 24140022
Front Immunol. 2017 Dec 11;8:1750
pubmed: 29321777
Sci Rep. 2021 Jan 8;11(1):79
pubmed: 33420169
Cancer Lett. 2016 Sep 28;380(1):272-80
pubmed: 26546872
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):246-257
pubmed: 28512002
JCI Insight. 2021 Jan 25;6(2):
pubmed: 33320838
Cancers (Basel). 2019 Nov 26;11(12):
pubmed: 31779269
Biochim Biophys Acta. 2016 Oct;1863(10):2481-97
pubmed: 26993058